Tatva Chintan reports 18.72% margin amid solvent and freight cost pressure
Management said solvent and freight trends should normalise within Q3, while new products and a greenfield project advance.
Filed 19 Oct 2026, 15:52 IST · after market close · Tatva Chintan Pharma Chem Ltd (TATVA)
Key takeaways
- Tatva Chintan reported consolidated net profit of Rs 21.45 cr, with operating profit of Rs 40.69 cr converting to an 18.72% operating margin.
- Management said solvent prices had risen 60%-100% and freight costs by more than 100%, putting pressure on raw-material and logistics costs.
- The company’s 18.72% operating margin was 1.42 percentage points above the 17.3% median for six reported Commodities-sector peers.
Price around the results
Operating profit converted to Rs 21.45 cr net profit
Tatva Chintan reported consolidated net profit of Rs 21.45 cr on revenue of Rs 217.32 cr. Operating profit was Rs 40.69 cr, while interest of Rs 2.71 cr and depreciation of Rs 10.79 cr reduced profit before tax to Rs 28.94 cr. Other income was Rs 1.75 cr, so reported profit was not materially dependent on non-operating income.
Solvent and freight costs were the main pressure points
Management said shortages in some solvents pushed their prices up 60%-100%, raising raw-material costs. The company also told analysts that freight rates had increased by more than 100% in some US and European sectors. Management said it plans to manage costs and progressively adjust customer pricing where appropriate.
Margin was above the reported peer median
Tatva Chintan’s 18.72% operating margin was 1.42 percentage points above the 17.3% median among six Commodities-sector peers that had reported. Management said it expects solvent and freight trends to normalise within Q3 and expects EBITDA margins to recover their prior trajectory.
Product pipeline and capacity expansion remain in focus
Management said recently commercialised agro products were performing well and a pharma product had started contributing to the business. It also said all five semiconductor chemical products were progressing through development, validation and customer qualification. The company said its greenfield project was progressing on schedule and would add capacity for existing businesses and new molecules, while hybrid-battery applications moved towards commercialisation.
Results were filed after market close
The consolidated results were filed after market close on 19 October 2026. No post-results share-price reaction was available at the time of reporting.
Q2FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q2FY27 |
|---|---|
| Revenue | ₹217 cr |
| Other income | ₹2 cr |
| Expenses | ₹177 cr |
| Operating profit | ₹41 cr |
| Operating margin (%) | 18.72% |
| Interest | ₹3 cr |
| Depreciation | ₹11 cr |
| Profit before tax | ₹29 cr |
| Tax | ₹7 cr |
| Net profit | ₹21 cr |
| EPS (₹) | ₹9.17 |
Operating margin of 18.72% compares with a Commodities sector median of 17.30% across 6 peers that have reported Q2FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The company said its semiconductor chemical products progressed through development, validation and customer qualification during the quarter.
- Recently commercialised agro products performed well and the pharma product began contributing to the business.
Guidance & outlook
- The company expects solvent and freight trends to normalise within the third quarter.
- The company expects revenue growth to maintain similar momentum and EBITDA margins to recover their healthy trajectory.
- The company plans to manage costs, progressively adjust customer pricing where appropriate and execute investments carefully.
Expansion
- The new greenfield project is progressing according to schedule and will add manufacturing capacity for existing businesses and new molecules.
New products
- The company has recently commercialised agro products and a pharma product that has begun contributing to the business.
New initiatives
- Hybrid-battery applications are progressing toward commercialisation and additional energy-storage products are being scaled up.
- The company is accelerating work on its product pipeline, with greater focus on piloting, process development and commercialisation.
- Five semiconductor chemical products are advancing through development, validation and customer qualification.
Competition
- The company describes global competition in its SDA business as limited.
Problems & risks
- Erratic shortages of some solvents caused solvent prices to rise by 60%-100%, increasing the company’s raw-material costs.
- Global freight rates increased sharply, by more than 100% in certain sectors of the US and Europe.
What to watch
- Whether operating margin holds above 18.72% as solvent and freight costs change.
- Whether solvent costs linked to the reported 60%-100% price increase ease within Q3.
- Progress from the five semiconductor chemical products and the greenfield project adding manufacturing capacity.